Abstract 30P
Background
Oral squamous cell carcinoma (OSCC) represents one of the six most common cancers in the world. The identification of new prognostic markers could help clinicians explore the biological characteristics of OSCC and develop more personalized treatment plans for patients based on their risk factors. The discovery and study of new prognostic markers of OSCC may help improve treatment outcomes through more accurate and effective treatment strategies, ultimately leading to improved survival and quality of life in patients with OSCC. The aim of this study was to identify the prognostic value of CDKN2A and miRNAs, involved in its regulation as markers of OSCC.
Methods
In the present study we have results of the examination and treatment of 70 patients with stage II–IV OSCC. miR-10b and -155 and mRNA of CDKN2A in tumor samples of patients with OSCC was analyzed by real-time reverse transcription polymerase chain reaction. Detection of p16INK4a was performed by simultaneous immunohistochemical assessment in tumor cells.
Results
We found a strong correlation of studied miRNAs expression with lymph node metastasis (r=0.56 for miR-10b and 0.59 for miR-155). Also, there is no differences in miR-10b and -155 between p16INK4a+ and p16INK4a- samples. p16INK4a status does not affect the association of both miRNAs with lymph node metastases.
Conclusions
The results indicate the relation between miR-10b and -155 and the presence of lymph node metastases of patients with OSCC and thus they can be used as prognostic markers of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract